Actively Recruiting
Evaluating Safety, Dosing, and Antiviral Effects of GS-4321 in Healthy Volunteers and Adults with Chronic Hepatitis Delta
Led by Gilead Sciences · Updated on 2026-08-27
200
Participants Needed
28
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, dosing, and effectiveness of the drug GS-4321 in both healthy individuals and people with chronic hepatitis delta CHD. The study has two phases Phase 1 focuses on safety, tolerability, and drug levels in healthy participants, while Phase 2 evaluates safety and effectiveness in participants with CHD. The study aims to understand how GS-4321 works and its impact on this liver condition. Participants in Phase 1 receive single escalating doses of GS-4321 or placebo, administered either under the skin or intravenously, to assess dose safety and drug behavior. In Phase 2, participants with CHD receive multiple escalating doses of GS-4321 over up to 96 weeks to evaluate its antiviral effects and safety. Throughout the study, participants undergo regular safety checks including monitoring for adverse events, clinical lab tests, and pharmacokinetic assessments. For those with CHD, measurements of viral RNA levels, liver stiffness, and liver enzyme levels are taken at multiple timepoints. The study also includes follow-up periods after dosing to monitor ongoing safety and treatment responses, lasting up to 144 weeks in total for some participants.
CONDITIONS
Brief Title
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Research Team
G
Gilead Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here